DOWNLOAD THIS SLIDE KIT

BROWSE SLIDES

Design

• VK2809: selected liver-targeted thyroid receptor β agonist

Endpoints

• Primary: change in LDL-cholesterol vs placebo
• Secondary: change in liver fat by MRI-PDFF
• Exploratory: changes in atherogenic lipoproteins

Baseline characteristics

Placebo-Adjusted % Change in LDL-C at W12

Relative change in MRI-PDFF liver fat content at W12, %

Absolute change in MRI-PDFF liver fat content at W12, %

• 66.7% of patients treated with VK2809 experienced a ≥ 50% decrease in liver fat content vs 18.2% in placebo-treated patients

Change in Lipoprotein(a) at W12, %

Change in Apolipoprotein B at W12, %

Summary of adverse events

• Good tolerability and safety
• No serious adverse events observed in any arm
• No dose-related trends in AEs
• Excellent gastro-intestinal tolerability

Summary

• VK2809 produced robust reduction in liver fat on MRI-PDFF in NAFLD patients after 12 weeks of oral dosing
• Up to 91% of patients dosed with VK2809 experienced a response as demonstrated by liver fat reductions ≥ 30% relative to baseline ; 67% experienced liver fat reductions ≥ 50%
• VK2809 produced significant reduction in LDL-C, triglycerides, Apo B, and Lp(a) relative to placebo in NAFLD patients
• VK2809 was safe and well-tolerated